Loss of In Vivo Replication Fitness of HIV-1 Variants Resistant to the Tat Inhibitor, DCA

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Apr 28

PMID 37112931

Authors

Lijun Ling

Ana R Leda

Nurjahan Begum

Rae Ann Spagnuolo

Angela Wahl

J Victor Garcia

Susana T Valente

Affiliations

Soon will be listed here.

Abstract

HIV resistance to the Tat inhibitor didehydro-cortistatin A (dCA) in vitro correlates with higher levels of Tat-independent viral transcription and a seeming inability to enter latency, which rendered resistant isolates more susceptible to CTL-mediated immune clearance. Here, we investigated the ability of dCA-resistant viruses to replicate in vivo using a humanized mouse model of HIV infection. Animals were infected with WT or two dCA-resistant HIV-1 isolates in the absence of dCA and followed for 5 weeks. dCA-resistant viruses exhibited lower replication rates compared to WT. Viral replication was suppressed early after infection, with viral emergence at later time points. Multiplex analysis of cytokine and chemokines from plasma samples early after infection revealed no differences in expression levels between groups, suggesting that dCA-resistance viruses did not elicit potent innate immune responses capable of blocking the establishment of infection. Viral single genome sequencing results from plasma samples collected at euthanasia revealed that at least half of the total number of mutations in the LTR region of the HIV genome considered essential for dCA evasion reverted to WT. These results suggest that dCA-resistant viruses identified in vitro suffer a fitness cost in vivo, with mutations in LTR and Nef pressured to revert to wild type.

Citing Articles

Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir.

Ling L, Kim M, Soper A, Kovarova M, Spagnuolo R, Begum N mBio. 2024; 15(9):e0163224.

PMID: 39136440 PMC: 11389399. DOI: 10.1128/mbio.01632-24.

Ripretinib inhibits HIV-1 transcription through modulation of PI3K-AKT-mTOR.

Cai J, Zhou J, Meng Z, Wu Z, Zhao J, Peng H Acta Pharmacol Sin. 2024; 45(8):1632-1643.

PMID: 38627462 PMC: 11272926. DOI: 10.1038/s41401-024-01282-z.

Transient CD4+ T cell depletion during suppressive ART reduces the HIV reservoir in humanized mice.

Ling L, De C, Spagnuolo R, Begum N, Falcinelli S, Archin N PLoS Pathog. 2023; 19(12):e1011824.

PMID: 38055722 PMC: 10699604. DOI: 10.1371/journal.ppat.1011824.

An Outbred Calf Model for Determining Innate Immune Sensing and Evolutionary Trajectories of a Cell Culture-Adapted Bovine Foamy Virus Variant.

Materniak-Kornas M, Kubis P, Sell B, Pougialis G, Lochelt M, Kuzmak J Viruses. 2023; 15(8).

PMID: 37632114 PMC: 10458543. DOI: 10.3390/v15081772.

References

Weiser K, Barton M, Gershoony D, DasGupta R, Cardozo T . HIV's Nef interacts with β-catenin of the Wnt signaling pathway in HEK293 cells. PLoS One. 2013; 8(10):e77865. PMC: 3795062. DOI: 10.1371/journal.pone.0077865. View

Razooky B, Pai A, Aull K, Rouzine I, Weinberger L . A hardwired HIV latency program. Cell. 2015; 160(5):990-1001. PMC: 4395878. DOI: 10.1016/j.cell.2015.02.009. View

Rouzine I, Weinberger A, Weinberger L . An evolutionary role for HIV latency in enhancing viral transmission. Cell. 2015; 160(5):1002-1012. PMC: 4488136. DOI: 10.1016/j.cell.2015.02.017. View

Weinberger L, Burnett J, Toettcher J, Arkin A, Schaffer D . Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 2005; 122(2):169-82. DOI: 10.1016/j.cell.2005.06.006. View

Denton P, Olesen R, Choudhary S, Archin N, Wahl A, Swanson M . Generation of HIV latency in humanized BLT mice. J Virol. 2011; 86(1):630-4. PMC: 3255928. DOI: 10.1128/JVI.06120-11. View

Espy N, Pacheco B, Sodroski J . Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. Virology. 2017; 508:90-107. PMC: 5516540. DOI: 10.1016/j.virol.2017.04.033. View

Sonza S, Mutimer H, OBrien K, Ellery P, Howard J, Axelrod J . Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages. J Virol. 2002; 76(24):12611-21. PMC: 136686. DOI: 10.1128/jvi.76.24.12611-12621.2002. View

Verdin E . DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol. 1991; 65(12):6790-9. PMC: 250767. DOI: 10.1128/JVI.65.12.6790-6799.1991. View

Denton P, Krisko J, Powell D, Mathias M, Kwak Y, Martinez-Torres F . Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One. 2010; 5(1):e8829. PMC: 2809117. DOI: 10.1371/journal.pone.0008829. View

10.

Kessing C, Nixon C, Li C, Tsai P, Takata H, Mousseau G . In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment. Cell Rep. 2017; 21(3):600-611. PMC: 5653276. DOI: 10.1016/j.celrep.2017.09.080. View

11.

Verhoef K, Koper M, Berkhout B . Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication. Virology. 1997; 237(2):228-36. DOI: 10.1006/viro.1997.8786. View

12.

Emiliani S, Fischle W, Ott M, Van Lint C, Amella C, Verdin E . Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol. 1998; 72(2):1666-70. PMC: 124653. DOI: 10.1128/JVI.72.2.1666-1670.1998. View

13.

Denton P, Othieno F, Martinez-Torres F, Zou W, Krisko J, Fleming E . One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol. 2011; 85(15):7582-93. PMC: 3147928. DOI: 10.1128/JVI.00537-11. View

14.

Chavez L, Calvanese V, Verdin E . HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells. PLoS Pathog. 2015; 11(6):e1004955. PMC: 4466167. DOI: 10.1371/journal.ppat.1004955. View

15.

Malim M, Emerman M . HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe. 2008; 3(6):388-98. DOI: 10.1016/j.chom.2008.04.008. View

16.

Mediouni S, Chinthalapudi K, Ekka M, Usui I, Jablonski J, Clementz M . Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat. mBio. 2019; 10(1). PMC: 6368365. DOI: 10.1128/mBio.02662-18. View

17.

Mousseau G, Clementz M, Bakeman W, Nagarsheth N, Cameron M, Shi J . An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe. 2012; 12(1):97-108. PMC: 3403716. DOI: 10.1016/j.chom.2012.05.016. View

18.

Lin X, Irwin D, Kanazawa S, Huang L, Romeo J, Yen T . Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J Virol. 2003; 77(15):8227-36. PMC: 165222. DOI: 10.1128/jvi.77.15.8227-8236.2003. View

19.

van Opijnen T, Kamoschinski J, Jeeninga R, Berkhout B . The human immunodeficiency virus type 1 promoter contains a CATA box instead of a TATA box for optimal transcription and replication. J Virol. 2004; 78(13):6883-90. PMC: 421681. DOI: 10.1128/JVI.78.13.6883-6890.2004. View

20.

Denton P, Estes J, Sun Z, Othieno F, Wei B, Wege A . Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008; 5(1):e16. PMC: 2194746. DOI: 10.1371/journal.pmed.0050016. View